Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab).
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D002170:Canada; D002675:Child, Preschool; D017277:Drug Approval; D005260:Female; D006801:Humans; D017589:Immunization Programs / Q000592:standards*; D007115:Immunization Schedule; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D000069455:Palivizumab; D011322:Primary Prevention / Q000379:methods; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D018113:Respiratory Syncytial Virus, Human / Q000276:immunology; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D014765:Viral Vaccines / Q000008:administration & dosage*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014765:Viral Vaccines; D000069455:Palivizumab